










Arterio-venous malformations (AVM) are 
one of various congenital vascular malfor-
mations that result from a failure of order-
ly resorption of the primitive blood ves-
sels in weeks 4–6 of gestation involving 
the vessels of both arterial and venous or-
igins and resulting in high-flow direct AV 
communications between different sized 
vessels (AVMs), vein malformations, and 
lymphatic malformations. An AVM is de-
fined as a high flow, low resistance com-
munication between the arterial and ve-
nous systems without an intervening nor-
mal capillary system. Thus, the pivotal 
function of the capillary system—which is 
to maintain the delicate balance between 
the high-pressure (arterial) and low-pres-
sure (venous) system—is not present, 
thereby, causing arterialized venous pres-
sure increases secondary to the AV shunts, 
and the tissue normal venous drainage 
slows and becomes delayed having diffi-
culty competing with the higher pressure 
arterialized veins. This leads to tissue ede-
ma due to venous hypertension [1].
Peripheral AVMs are the least common 
type representing 5–20% of all congenital 
vascular malformations. Most of the cur-
rent data regarding incidence and preva-
lence of AVMs are based on cerebrospinal 
AVMs. They are rare and usually go un-
detected until clinical symptoms appear in 
patients aged 20–40 years [2].
AVMs are the most complex type of 
congenital vascular malformations with 
significant hemodynamic alterations to 
both the arterial and venous systems, 
which if they are large and centrally po-
sitioned in the body (e.g., shoulder, chest, 
abdomen, pelvis, buttock) can induce high 
flow cardiac output failure (right heart 
volume overload), arterial insufficiency 
(steal) in the affected tissue, and chronic 
venous hypertension.
Classification
Two classifications were proposed to im-
prove AVM management: the Schobinger 
clinical classification and an arteriograph-
ic classification. The Schobinger classifi-
cation (. Tab. 1) was designed to assess 
AVM lesions in different clinical stages 
and clinical conditions more accurately 
based on the patient’s clinical status and 
to select the best suited time for manage-
ment as a practical guideline.
The arteriographic classification of 
AVMs was proposed to better define po-
tential treatment strategies. Several classi-
fication systems have been published. A 
cerebrovascular congenital AVM classi-
fication system published in 1993 [3] and 
a peripheral vascular AVM classification 
system [4, 5] published in 2006 are strik-
ingly similar regarding the angioarchitec-
ture of high-flow AVMs.
The arteriographic classification was 
further adjusted by angioarchitecture ad-
ditions not described in these two classi-
fication systems by W. Yakes, adding the 
Yakes type I [direct artery-to-vein con-
nections, e.g., as is seen in pulmonary ar-
teriovenous fistulas (AVFs)] and Yakes 
type IV AVMs (characterized by a net-
work of innumerable AVFs without a de-
fined nidus infiltrating entire tissue with 
capillary beds interspersed among the in-
numerable AVFs) and a further modifi-
cation of the previous two classification 
systems with Yakes types II, IIIa, and IIIb 
(. Tab. 2, . Fig. 1).
Management
AVMs remain the most challenging mal-
formation among various congenital vas-
cular malformations due to their potential 





the affected tissue and the subsequent he-
modynamic consequences related to arte-
rial steal and venous hypertensive chang-
es. Clinical manifestations associated with 
AVM are dependent on the anatomical lo-
cation and may produce cardiac failure, 
local venous hypertension with abnormal 
tissue changes, and arterial steal. In addi-
tion, local effects of AVMs may include 
ulcerations that may be nonhealing and 
chronic, bleeding and infections in those 
ulcerated tissues, necrosis of the affected 
tissues, and gangrene if the arterial vascu-
lar steal is significant.
Hormonal factors known to trigger 
progression of clinical symptoms in vas-
cular malformations that have been pre-
viously quiescent include the onset of pu-
berty/menarche, pregnancy, birth con-
trol pills, direct trauma, surgery with par-
tial resection of the AVM lesion, proxi-
mal ligation of prominent feeding arter-
ies, “skeletonization” surgical exclusion 
procedures, etc. All these produce neo-
vascular stimulation enlarging the AVM 
and worsening its symptoms in the Schob-
inger classification.
An ill-planned and improper treat-
ment strategy (incomplete resection, sur-
gical ligation/skeletonization and/or prox-
imal coil embolization of the feeding ar-
teries) can stimulate an AVM lesion to 
transform from a dormant state to a pro-
liferative state, resulting in AVM growth 
with advancement of the Schobinger clas-
sification to higher stages of symptomo-
tology.
The main goal of treatment should be 
to elimination the nidus by vascular oc-
clusion procedures or complete surgical 
extirpation of the AVM. Partial resection 
will result in lesion recurrence and en-
largement with increased symptoms by 
neovascular stimulation.
Overview of endovascular 
occlusive procedures
Endovascular therapy with various em-
bolization and sclerotherapy modalities 
is reported in the  literature by many vas-
cular malformation centers as the pre-
ferred therapeutic option for the majority 
of AVM lesions, rather than surgical extir-
pation [7–10]. Precise delivery of the em-
bolic agent to ablate the AVM nidus is re-
quired for successful endovascular ther-
apy, to minimize complications, and to 
achieve a long-term cure.
A combination of approaches utilizing 
any of the three routes of delivery of em-
bolic agents (transarterial, transvenous, 
direct puncture) may be required to ablate 
the AVM. Multisession endovascular ther-
apy is preferred and every effort should be 
exercised to minimize the risks of embo-
lo-sclerotherapy during each session. The 
most appropriate embolic agents for pri-
mary control of AVM include transcathe-
ter embolization, direct puncture emboli-
zation, and retrograde vein embolization 
approaches primarily using ethanol in 
Yakes types II, IIIa, and IIIb AVMs. Coils 
and other mechanically occlusive devic-
es can be curative in Yakes type I AVFs. 
Coils can also lessen complications when 
densely packed in the aneurysmal veins of 
Yakes types IIIa and IIIb AVMs. In Yakes 
type IV AVMs, a 50–50% mixture of etha-
nol and contrast as an embolic agent is cu-
rative in these infiltrative lesions and can 
spare the capillary beds from occlusion. 
The use of nBCA (n-butyl-2-cyanoacry-
late) and/or Onyx are completely inade-
quate to cure or provide long-term control 
for AVMs as a primary form of therapy. In 
the literature, it is reported that these po-
lymerizing embolic agents are palliative at 
best and recurrences are common [11–15].
Embolic agents
Many embolic agents have been used in 
the treatment of AVMs. Particulate agents, 
which include polyvinyl alcohol (PVA) 
particles, microspheres, gelfoam, and col-
lagen powders, have been used to emboli-
ze AVMs. Their use, alone or in combina-
tion with other agents, is well documented 
in the literature and is palliative with high 












AV arteriovenous, AVM arteriovenous malformation, PVR peripheral vascular resistance, US ultrasound.
Tab. 2  Yakes classification of high-flow AVM angioarchitecture [6]
Type I A direct artery/arteriole to vein/venule connection
Direct AV connections can be treated with fibered coils, wires, Amplatzer plugs. Mechanical 
device occlusion can be curative
Type II Multiple arteries/arterioles connecting through an intervening “nidus” without any in-
tervening capillary beds draining into multiple out-flow veins.





Ethanol and/or coils can be curative
Type IIIb Multiple inflow arterioles shunting into an aneurysmal vein with multiple outflow veins. 
(AV fistulae which infiltrate the wall of the aneurysmal vein with multiple outflow veins).







A 50–50% mixture of ethanol and non-ionic contrast can be curative in this lesion type
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Unfortunately, these agents do not 
possess properties that are well suited for 
treating AVMs. The particles are often ei-
ther too large and occlude the vessels prox-
imal to the nidus, or too small traveling 
through the AV shunt causing nontarget 
embolization. Since they are not well suit-
ed to treat AVMs, their primary purpose 
is to alter the hemodynamics of the lesion 
to improve the possibility for surgical re-
section, which is difficult to achieve.
Fibered and non-fibered coils
Coils are designed to mechanically oc-
clude larger vessels and are not able to 
penetrate into the AVM nidus, as they are 
an endovascular occluding device sized to 
the diameter of the artery/vein that is be-
ing embolized. When used as a transarte-
rial embolic occlusive device, the result is 
proximal arterial ligation that is not cu-
rative and will cause neovascular stimula-
tion of the AVM, thus, stimulating growth 
of new arteries/arterioles to the AVM and 
worsening of the situation [22].
A major disadvantage of coil emboliza-
tion therapy is that its mechanism of ac-
tion is limited to the occlusion and subse-
quent thrombosis of the artery or vein in 
which it is placed. Permanent damage to 
the blood vessel endothelium does not oc-
cur, thus, allowing for subsequent regen-
eration or recovery of the endothelium. 
This can result in recanalization with re-
currence of the lesion.
However, coils can be extremely effec-
tive and curative in AVM treatment when 
placed in the aneurysmal outflow veins and 
is a definitive treatment. This is particular-
ly effective where there is a single AV con-
nection (Yakes type I) and multiple arter-
ies connect to a single draining vein (Yakes 
types IIIa/IIIb AVM lesions). In these types 
of AVM, occlusion of the venous outflow 
with coils can be very effective and dramat-
ically reduces the risk of tissue injury and 
complications associated with transarteri-
al ethanol embolization.
In AVMs that have an aneurysmal 
dilatation of the draining vein, with sin-
gle outflow vein (Yakes IIIa) and multi-
ple outflow veins arising from it (Yakes 
type IIIb), coil embolization can be used 
in combination with ethanol to achieve a 
definitive treatment. Once flow has been 
slowed in the outflow veins by the place-
ment of the coils, the injection of abso-
lute ethanol can then reflux into the many 
vein fistulae in the wall of this aneurys-
mal vein to allow permanent occlusion 
of the AVM. This “retrograde vein oc-
clusion” technique in curative treatment 
of high-flow vascular malformations was 
first described by Yakes et al. in 1990 [23] 
and later confirmed by Jackson et al. [24] 
and Cho et al. [25].
Absolute ethanol
The curative potential of absolute ethanol 
as an AVM embolic/sclerosant agent lies 
in the fact that it destroys the endotheli-
al cells on the vascular wall by precipitat-
ing its protoplasm (endothelial cells lin-
ing arteries, veins, capillaries, lymphatics) 
and causes fractures of the vascular wall to 
the level of the internal elastic lamina. Be-
cause the endothelial cells are destroyed, 
the phenomena of neovascular stimula-















































































cretion of angiogenesis factors, and the 
recanalization phenomenon due to secre-
tion of chemotactic cellular factor to carry 
out intravascular debris, is noticeably ab-
sent and the potential for a permanent oc-
clusion is now possible [26–34].
Because the endothelial cells are de-
nuded from the vascular wall, its proto-
plasm precipitated, and the vascular wall 
is fractured to the level of the internal elas-
tic lamina, platelet aggregation occurs on 
the denuded vascular wall surface. This 
thrombotic process progressively occludes 
the vascular lumen from the vascular wall 
surface to the central lumen. There will 
be no more chemotactic cellular factors 
and angiogenesis factors secreted since 
the endothelial cells are completely de-
stroyed [35].
However, the risk of cardiopulmonary 
complications during ethanol sclerother-
apy administration is significant; there-
fore, appropriate measures should be tak-
en which include administration of gener-
al anesthesia and close cardiopulmonary 
monitoring. Use of a pulmonary artery 
catheter during ethanol sclerotherapy will 
allow continuous pulmonary artery pres-
sure monitoring. Shin et al. [36] report-
ed that if no more than 0.14 ml ethanol/kg 
body weight is embolized every 10 min, no 
cardiopulmonary complications will oc-
cur [37, 38].
Pulmonary hypertension is a poten-
tially fatal complication associated with 
ethanol sclerotherapy and occurs when 
a significant dose of ethanol is allowed to 
reach to the lungs. The etiology of pul-
monary hypertension is felt to be related 
to either pulmonary arterial spasm or ex-
tensive microthromboembolization. The 
development of pulmonary hypertension 
can lead to subsequent cardiopulmonary 
arrest if not controlled effectively.
A total dose of ethanol used during an 
embolization procedure should be less 
than 1 ml/kg, since volumes greater than 
this can be toxic. Limiting ethanol in-
jections to 0.14 ml ethanol/kg ideal body 
weight every 10 min will be able to obvi-
ate the need of a pulmonary artery cath-
eter when anticipating large injections of 
ethanol in large lesions [39]. By adher-
ing to these principles, the risk of etha-
nol flowing to the pulmonary circulation, 
thus, causing pulmonary vascular spasm 
with subsequent acute right heart failure, 
is obviated.
Because absolute ethanol is associated 
with various complications and morbidity, 
safe use of ethanol in AVM embolization 
requires accurate delivery into the nidus 
by precise placement solely in the AVM 
nidus vasculature that is nonnutritive and 
without capillaries. Proximal injection of 
ethanol into a feeding artery would cause 
severe tissue necrosis by destroying nutri-
tive capillary beds.
In order to enhance the denaturat-
ing or sclerosing effect on the endotheli-
al cells, lowering the flow in the AVM it-
self is a highly effective technique to al-
low the injected ethanol to remain in lon-
ger contact with the cells. Decreasing the 
flow through the lesion can be achieved in 
different ways (. Fig. 2):
F  arterial approach: this approach can 
make use of occlusion balloons,
F  direct puncture injection of the scle-
rosing material, or
F  direct puncture or retrograde trans-
catheter venous approach. Occlusion 
of the aneurysmal vein with coils can 
be curative.
To decrease postembolization swelling 
in the endovascularly treated area, intra-
venous dexamethasone is routinely used 
prior to the procedure as well as nonste-
roidal anti-inflammatory agents and ste-
roid therapy for 5 days postprocedure, 
thus, greatly reducing the risk of devel-
oping compartment syndrome or subse-
quent possible nerve injuries due to ede-
ma. Accurate and meticulous emboliza-
tion techniques, treating only the AVM, 
total avoidance of ethanol embolization 
of capillary beds, use of fibered coils in 
the vein approach in Yakes types I, IIIa, 
IIIb AVMs, will greatly diminish compli-
cations from vascular malformation en-
dovascular treatment procedures in these 
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(Ausgaben 05/2013 bis 04/2014) in der 
 Gefässchir urgie publiziert wurde. 
Mit dem Preisgeld die 



























Preisverleihung im Rahmen der 
30. Jahrestagung der Deutschen 
Gesellschaft für Gefäßchirurgie 
und Gefäßmedizin (DGG)
Die Verleihung des 5. Julius-Springer-Preises 
Gefäßmedizin erfolgt im Rahmen der 30. Jah-
restagung der Deutschen Gesellschaft für Ge-
fäßchirurgie und Gefäßmedizin (DGG) vom  
24.-27. September 2014 in Hamburg.
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